Jonas Neher

Group Leader

Hertie Institute for clinical brain research
Country flagGermany
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (6)

Neuroinflammation is a key modulator of Alzheimer’s disease (AD) risk, yet the impact of non-genetic inflammatory risk factors – such as systemic inflammation – remains poorly defined. Building on our previous work, here we show that 9 months after systemic lipopolysaccharide (LPS) challenge in APP23 mice, microglia-plaque interaction is disturbed and shifts Aβ aggregates toward a less compacted state, as revealed by conformation-sensitive amyloid dyes. Importantly, these structural changes are associated with increased plaque-associated neuritic dystrophy, phenocopying the effects of microglial risk genes. Generalising these findings, we show that across aging in APP23 and APPPS1 mice, and in AD patient tissue, non-compacted amyloid and microgliosis – but not compacted amyloid – are consistent predictors of neuritic damage. Notably, both in mouse and human tissue, ex vivo amyloid-PET signal largely reflects compacted but not non-compacted amyloid load. Our findings suggest that genetic and environmental risk factors converge on shared mechanisms of impaired microglial-plaque interaction and amyloid restructuring, and that commonly used amyloid-PET measures insufficiently capture amyloid states that define the severity of neuritic damage, with important implications for clinical trials in AD.

Year:

2026

Microglia, the primary myeloid cells of the brain, are crucial for maintaining brain homeostasis and are implicated in various neuropathological processes. Microglial identity and function are determined by their ontogeny and the brain microenvironment. Therefore, model systems that faithfully reproduce mature human microglial molecular and functional phenotypes are crucial for understanding their role in brain health and disease. Here, we demonstrate that microglial precursors derived from induced pluripotent stem cells (iPSCs) can integrate and mature in murine organotypic brain slices. Importantly, we achieve a near-complete replacement of murine with human microglia and demonstrate that their maturation is driven solely by the tissue environment through previously underappreciated cross-species human colony stimulating factor 1 receptor (hCSF1R) binding of murine interleukin 34 (IL34). The iPSC-derived microglia in the chimeric brain slice cultures (cBSCs) exhibit functional responses and develop transcriptional states reminiscent of adult human microglia while responding to developing -synuclein proteopathy with heightened inflammatory state. Thus, our findings establish cBSCs as a tool for examining human microglia in a physiologically relevant environment, while maintaining the experimental flexibility of an in vitro system for mechanistically investigating neuropathological microglial responses.

Year:

2025

The prevailing view frames microglia and macrophages as guardians against amyloid beta (Aβ) accumulation in Alzheimer’s disease (AD). Here, we overturn this paradigm by demonstrating that human phagocytic cells—including differentiated THP-1 macrophages and iPSC-derived microglia—are not merely passive responders but active producers of extracellular, seeding-competent Aβ42 fibrils, the amyloid species most strongly linked to parenchymal plaque formation and neurodegeneration. These cell-generated aggregates differ structurally and functionally from synthetic fibrils, exhibiting heightened seeding activity and the ability to cross-seed tau aggregation, a key driver of AD progression. Notably, Aβ42 fibril formation in this system requires active cellular processes and is exacerbated by loss of TREM2, a major AD risk gene. Transcriptomic profiling reveals an early inflammatory response resembling microglial states observed in human AD models, positioning this system as a tractable, human-relevant platform to dissect the interplay between Aβ aggregation, innate immunity, and genetic susceptibility. Our findings suggest that macrophages and microglia play a dual role in AD, acting both as responders and inadvertent catalysts of pathogenic amyloid formation, with implications for early therapeutic intervention. Significance Statement How amyloid plaques emerge and spread in Alzheimer’s disease remains a critical unanswered question. Here, we show that human immune cells—including brain-resident microglia—can actively generate Aβ42 fibrils, the form of amyloid most strongly linked to neurodegeneration. These cell-produced fibrils not only seed further amyloid buildup but also trigger tau aggregation, a key event in disease progression. We further demonstrate that genetic risk factors like TREM2 amplify this process. Our findings reveal a direct link between immune cell activity, genetic susceptibility, and the earliest stages of Alzheimer’s pathology, offering new insights into disease mechanisms and potential intervention points.

Year:

2025

Medin, a vascular amyloid derived from MFG-E8, is the most prevalent form of localized human amyloid and co-localizes with Aβ in Alzheimer’s disease and, in particular, cerebral amyloid angiopathy (CAA). While it was shown that medin can promote Aβ aggregation, it remains unclear whether this amyloid-amyloid interaction affects the structure of the resulting fibrils. Here, we investigate how medin modulates Aβ40 fibril assembly in vitro using cryo-electron microscopy, aggregation kinetics, and immunogold electron microscopy. We show that medin accelerates Aβ40 aggregation, co-assembles into hybrid fibrils, and modulates fibril morphology. Cryo-EM analysis reveals two fibril populations: one corresponding to a previously described in vitro Aβ40 morphology, and a second, previously unobserved polymorph with Aβ42-like features, including a structured N-terminus and a compact hydrophobic C-terminal core. The presence of a peripheral, unresolved cryo-EM density near the fibril surface suggests that the new polymorph is stabilised through heterotypic interactions, yet the atomic details remain unresolved, likely due to substantial structural heterogeneity. Rather than representing a limitation, this highlights how not all determinants critical for fibril assembly are necessarily ordered or resolvable in the final fibril structure, reflecting the inherent dynamic and heterogeneous nature of amyloid interactions. Our findings provide structural evidence that heterotypic co-aggregation can redirect Aβ40 into distinct conformational states and suggest that dynamic or transient interactions contribute to fibril polymorphism beyond what can be fully captured in static structural models.

Year:

2025

Alzheimer’s disease (AD) is often accompanied by early non-cognitive symptoms, including olfactory deficits, such as hyposmia and anosmia 1 . These have emerged as solid predictors of cognitive decline, but the underlying mechanisms of hyposmia in early AD remain elusive 2 . Pathologically, one of the brain regions affected earliest is the brainstem locus coeruleus (LC), the main source of the neurotransmitter noradrenalin (NA) and, a well-known neuromodulator of olfactory information processing 3 . Here we show that early and distinct loss of noradrenergic input to the olfactory bulb (OB) coincides with impaired olfaction in a mouse model of AD, even before pronounced appearance of extracellular amyloid plaques. Mechanistically, OB microglia detect externalized phosphatidylserine and MFG-E8 on hyperactive LC axons and subsequently initiate their clearance. Translocator protein 18 kDa (TSPO) knockout reduces phagocytosis, preserving LC axons and olfaction. Importantly, patients with prodromal AD display elevated TSPO-PET signals in the OB, similarly to APP NL-G-F mice. We further confirm early LC axon degeneration in post-mortem OBs in patients with early AD. Collectively, we uncover an underlying mechanism linking early LC system damage and hyposmia in AD. Our work may help to improve early diagnosis of AD by olfactory testing and neurocircuit analysis and consequently enable early intervention.

Year:

2024

Microglia, the major population of brain‐resident macrophages, are now recognized as a heterogeneous population comprising several cell subtypes with different (so far mostly supposed) functions in health and disease. A number of studies have performed molecular characterization of these different microglial activation states over the last years making use of “omics” technologies, that is transcriptomics, proteomics and, less frequently, epigenomics profiling. These approaches offer the possibility to identify disease mechanisms, discover novel diagnostic biomarkers, and develop new therapeutic strategies. Here, we focus on epigenetic profiling as a means to understand microglial immune responses beyond what other omics methods can offer, that is, revealing past and present molecular responses, gene regulatory networks and potential future response trajectories, and defining cell subtype‐specific disease relevance through mapping non‐coding genetic variants. We review the current knowledge in the field regarding epigenetic regulation of microglial identity and function, provide an exemplary analysis that demonstrates the advantages of performing joint transcriptomic and epigenomic profiling of single microglial cells and discuss how comprehensive epigenetic analyses may enhance our understanding of microglial pathophysiology.

Year:

2024

Collaborators (15)

Joost Schymkowitz

Scientific vice-director

Katholieke Universiteit Leuven

BELGIUM
View details

Tammaryn Lashley

University College London

UNITED KINGDOM
View details

Nikolaos Louros

Assistant Professor

University of Texas Southwestern Medical Center

UNITED STATES
View details

Nicolas Casadei

Universitätsklinikum Tübingen

GERMANY
View details

Matthias Brendel

-

GERMANY
View details

Deborah Kronenberg-Versteeg

University of Tübingen

GERMANY
View details

Maarten Dewilde

Professor

KU Leuven

BELGIUM
View details

Jillian Madine

Senior Lecturer

University of Liverpool

UNITED KINGDOM
View details

Bettina Weigelin

W2 Professor

University of Tübingen

GERMANY
View details

Robert Perneczky

Professor

Ludwig-Maximilians-Universität München

GERMANY
View details

Bart De Strooper

KU Leuven

BELGIUM
View details

Mathias Jucker

Full Professor, Department Head

-

GERMANY
View details

Thomas Wuttke

Eberhard Karls Universität Tübingen

GERMANY
View details

Dietmar Rudolf Thal

Professor for Neuropathology

Katholieke Universiteit Leuven

BELGIUM
View details

Lars Paeger

Principal Investigator, Head of In vivo Electrophysiology Laboratory

Deutsches Zentrum für Neurodegenerative Erkrankungen

GERMANY
View details